Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
Mayo Clinic
Columbia University
Yale University
National Institutes of Health Clinical Center (CC)
Northwestern University
NYU Langone Health
National Cancer Institute (NCI)
National Cancer Institute (NCI)